Yang, J. C. et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 13, 539–548 (2012).
Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
Yun, C.-H. et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217–227 (2007).
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
Paez, J. G. et al. EGFRmutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169–181 (2007).
Robichaux, J. P. et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597, 732–737 (2021).
Campo, M. et al. Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies. J. Thorac. Oncol. 11, 2022–2026 (2016).
Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560–562 (2015).
Passaro, A., Jänne, P. A., Mok, T. & Peters, S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat. Cancer 2, 377–391 (2021).
Russo, A. et al. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int. J. Mol. Sci. 20, 1431 (2019).
Passaro, A. et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J. Thorac. Oncol. 16, 764–773 (2021).
Yang, J. C. et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J. Thorac. Oncol. 15, 803–815 (2020).
Janning, M. et al. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann. Oncol. 33, 602–615 (2022).
Pretelli, G., Spagnolo, C. C., Ciappina, G., Santarpia, M. & Pasello, G. Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): new lights for an unmet medical need. Int. J. Mol. Sci. 24, 8878 (2023).
Kohsaka, S. et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci. Transl. Med. 9, 416 (2017).
Chakroborty, D. et al. An unbiased in vitro screen for activating epidermal growth factor receptor mutations. J. Biol. Chem. 294, 9377–9389 (2019).
An, L. et al. Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors. Transl. Res. 255, 14–25 (2023).
Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).
Nishida, K. et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729 (2016).
Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).
Findlay, G. M. et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562, 217–222 (2018).
Meitlis, I. et al. Multiplexed functional assessment of genetic variants in CARD11. Am. J. Hum. Genet. 107, 1029–1043 (2020).
Buckley, M. et al. Saturation genome editing maps the functional spectrum of pathogenic VHL alleles. Nat. Genet. 56, 1446–1455 (2024).
Hanna, R. E. et al. Massively parallel assessment of human variants with base editor screens. Cell 184, 1064–1080 (2021).
Cuella-Martin, R. et al. Functional interrogation of DNA damage response variants with base editing screens. Cell 184, 1081–1097 (2021).
Kim, Y. et al. High-throughput functional evaluation of human cancer-associated mutations using base editors. Nat. Biotechnol. 40, 874–884 (2022).
Sanchez-Rivera, F. J. et al. Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants. Nat. Biotechnol. 40, 862–873 (2022).
Perner, F. et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615, 913–919 (2023).
Erwood, S. et al. Saturation variant interpretation using CRISPR prime editing. Nat. Biotechnol. 40, 885–895 (2022).
Findlay, G. M., Boyle, E. A., Hause, R. J., Klein, J. C. & Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120–123 (2014).
Radford, E. J. et al. Saturation genome editing of DDX3X clarifies pathogenicity of germline and somatic variation. Nat. Commun. 14, 7702 (2023).
Huang, H. et al. Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variants. Preprint at bioRxiv https://doi.org/10.1101/2023.12.14.571597 (2023).
Chen, P. J. et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 184, 5635–5652 (2021).
Li, X. et al. Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure. Nat. Commun. 13, 1669 (2022).
Yu, G. et al. Prediction of efficiencies for diverse prime editing systems in multiple cell types. Cell 186, 2256–2272 (2023).
Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19, 269–285 (2018).
Stoler, N. & Nekrutenko, A. Sequencing error profiles of Illumina sequencing instruments. NAR Genom. Bioinform. 3, lqab019 (2021).
Broad Institute of Harvard and MIT. DepMap: the cancer dependency map project at Broad Institute. DepMap https://depmap.org/portal/ (2020).
Hart, T. et al. High-Resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515–1526 (2015).
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR–Cas9. Nat. Biotechnol. 34, 184–191 (2016).
Doench, J. G. Am I ready for CRISPR? A user’s guide to genetic screens. Nat. Rev. Genet. 19, 67–80 (2018).
Ren, X. et al. High-throughput PRIME-editing screens identify functional DNA variants in the human genome. Mol. Cell 83, 4633–4645 (2023).
Gould, S. I. et al. High-throughput evaluation of genetic variants with prime editing sensor libraries. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02172-9 (2024).
Chardon, F. M. et al. A multiplex, prime editing framework for identifying drug resistance variants at scale. Preprint at bioRxiv https://doi.org/10.1101/2023.07.27.550902 (2023).
Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 15, 554 (2014).
Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240–2247 (2013).
Mok, T. S. et al. Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629–640 (2016).
Tan, C.-S. et al. Third generation EGFR TKIs: current data and future directions. Mol. Cancer 17, 29 (2018).
Kobayashi, Y. et al. Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer. Mol. Cancer Ther. 16, 357–364 (2017).
Liu, Y. et al. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. Lung Cancer 118, 1–5 (2018).
Yang, Z. et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin. Cancer Res. 24, 3097–3107 (2018).
Li, M. et al. L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment. Discov. Oncol. 13, 72 (2022).
Sueoka-Aragane, N. et al. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer Med. 10, 3873–3885 (2021).
Carlo, D. E. et al. Acquired EGFR C797G mutation detected by liquid biopsy as resistance mechanism after treatment with osimertinib: a case report. In Vivo 35, 2941–2945 (2021).
Nie, K. et al. Mutational profiling of non-small-cell lung cancer resistant to osimertinib using next-generation sequencing in chinese patients. BioMed Res. Int. 2018, 9010353 (2018).
Avizienyte, E., Ward, R. A. & Garner, A. P. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem. J. 415, 197–206 (2008).
Bean, J. et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res. 14, 7519–7525 (2008).
Zhang, L. et al. Molecular characteristics of the uncommon EGFR exon 21 T854A mutation and response to osimertinib in patients with non-small cell lung cancer. Clin. Lung Cancer 23, 311–319 (2022).
Xing, P. et al. Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. J. Cell. Mol. Med. 23, 6812–6821 (2019).
Brown, B. P. et al. Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Proc. Natl Acad. Sci. USA 119, e2206588119 (2022).
Malapelle, U. et al. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev. Mol. Diagn. 17, 209–215 (2017).
Yu, Z. et al. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 67, 10417–10427 (2007).
Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137–1149 (2006).
Hu, Y. et al. Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31,414 cancer patients. Clin. Cancer Res. 23, 7351–7359 (2017).
Leonetti, A. et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer 121, 725–737 (2019).
Brown, B. P. et al. On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation. Clin. Cancer Res. 25, 3341–3351 (2019).
Wei, Y. et al. Afatinib as a potential therapeutic option for patients with NSCLC with EGFR G724S. JTO Clin. Res. Rep. 2, 100193 (2021).
Zhang, Q. et al. EGFR L792H and G796R: two novel mutations mediating resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib. J. Thorac. Oncol. 13, 1415–1421 (2018).
Klempner, S. J., Mehta, P., Schrock, A. B., Ali, S. M. & Ou, S. I. cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. Lung Cancer 8, 241–247 (2017).
Zheng, D. et al. EGFR G796D mutation mediates resistance to osimertinib. Oncotarget 8, 49671–49679 (2017).
Liu, Y., Yang, Q. & Zhao, F. Synonymous but not silent: the codon usage code for gene expression and protein folding. Annu. Rev. Biochem. 90, 375–401 (2021).
John, T. et al. Uncommon EGFR mutations in non-small-cell lung cancer: a systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol. 76, 102080 (2022).
Mathis, N. et al. Machine learning prediction of prime editing efficiency across diverse chromatin contexts. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02268-2 (2024).
Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402–410 (2022).
Mantaci, S., Restivo, A. & Sciortino, M. Distance measures for biological sequences: some recent approaches. Int. J. Approx. Reason. 47, 109–124 (2008).
Kim, H. K. et al. In vivo high-throughput profiling of CRISPR–Cpf1 activity. Nat. Methods 14, 153–159 (2017).
Dang, Y. et al. Optimizing sgRNA structure to improve CRISPR–Cas9 knockout efficiency. Genome Biol. 16, 280 (2015).
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
Miller, S. M. et al. Continuous evolution of SpCas9 variants compatible with non-G PAMs. Nat. Biotechnol. 38, 471–481 (2020).
Briggs, A. W. et al. Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from individual monomers. Nucleic Acids Res. 40, e117 (2012).
Kim, S., Bae, T., Hwang, J. & Kim, J. S. Rescue of high-specificity Cas9 variants using sgRNAs with matched 5′ nucleotides. Genome Biol. 18, 218 (2017).
Park, J., Lim, K., Kim, J. S. & Bae, S. Cas-analyzer: an online tool for assessing genome editing results using NGS data. Bioinformatics 33, 286–288 (2017).
Koblan, L. W. et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat. Biotechnol. 36, 843–846 (2018).
Heckl, D. & Charpentier, E. Toward whole-transcriptome editing with CRISPR–Cas9. Mol. Cell 58, 560–562 (2015).
Shalem, O. et al. Genome-scale CRISPR–Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
DeWeirdt, P. C. et al. Optimization of AsCas12a for combinatorial genetic screens in human cells. Nat. Biotechnol. 39, 94–104 (2021).
Chen, W. et al. Massively parallel profiling and predictive modeling of the outcomes of CRISPR/Cas9-mediated double-strand break repair. Nucleic Acids Res. 47, 7989–8003 (2019).
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
Sondka, Z. et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 52, D1210–D1217 (2024).
Ettinger, D. S. et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 20, 497–530 (2022).
Ten Hacken, E. et al. High throughput single-cell detection of multiplex CRISPR-edited gene modifications. Genome Biol. 21, 266 (2020).
Cross, D. A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046–1061 (2014).
Zhang, K. R. et al. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Sci. Transl. Med. 13, eabg6428 (2021).
